Context Therapeutics (Context Therapeutics) Cash Flow from Financing : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Context Therapeutics Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Mar. 2024, Context Therapeutics paid $0.00 Mil more to buy back shares than it received from issuing new shares. It received $0.00 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, Context Therapeutics spent $0.00 Mil on financial activities for the three months ended in Mar. 2024.

Context Therapeutics Cash Flow from Financing Historical Data

The historical data trend for Context Therapeutics's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Context Therapeutics Cash Flow from Financing Chart

Context Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash Flow from Financing

1.96

1.15

58.39

-0.10

Context Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash Flow from Financing	Get a 7-Day Free Trial													-	-	-	-	-

Context Therapeutics Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Context Therapeutics's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

	Cash Flow from Financing		(A: Dec. 2023 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0	+	0	+	0	+	0	+	0	+	0
=	0.00

Context Therapeutics's Cash from Financing for the quarter that ended in Mar. 2024 is:

	Cash Flow from Financing		(Q: Mar. 2024 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0	+	0	+	0	+	0	+	0	+	0
=	0.00

Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Context Therapeutics (NAS:CNTX) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Context Therapeutics's issuance of stock for the three months ended in Mar. 2024 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Context Therapeutics's repurchase of stock for the three months ended in Mar. 2024 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Context Therapeutics's net issuance of debt for the three months ended in Mar. 2024 was $0.00 Mil. Context Therapeutics received $0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Context Therapeutics's net issuance of preferred for the three months ended in Mar. 2024 was $0.00 Mil. Context Therapeutics paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Context Therapeutics's cash flow for dividends for the three months ended in Mar. 2024 was $0.00 Mil. Context Therapeutics received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Context Therapeutics's other financing for the three months ended in Mar. 2024 was $0.00 Mil. Context Therapeutics received $0.00 Mil on other financial activities.

Context Therapeutics Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Context Therapeutics's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Context Therapeutics (Context Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Context Therapeutics Inc (NAS:CNTX) » Definitions » Cash Flow from Financing

Comparable Companies

Traded in Other Exchanges

6K9:Germany

Address

2001 Market Street, Suite 3915, Unit No. 15, Philadelphia, PA, USA, 19103

Website

https://www.contexttherapeutics.com

Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer.

Executives

Martin A. Lehr	director, officer: Chief Executive Officer	3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Jennifer Lynn Minai-azary	officer: Chief Financial Officer	110 MILLER AVENUE, SUITE 100, ANN ARBOR MI 48104
Alex C. Levit	officer: Chief Legal Officer, Corp. Sec	3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Tarek Sahmoud	officer: Chief Medical Officer	3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Richard J Berman	director	305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Jennifer Evans Stacey	director	AUXILIUM PHARMACEUTICALS, INC., 160 WEST GERMANTOWN PIKE, NORRISTOWN PA 19401
Linda West	director	C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BLVD., #110, MALVERN PA 19355
Evan G. Dick	officer: SVP of R&D	3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
William F. Rencher	officer: Head of CMC and Regulatory	3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Philip W. Kantoff	director	3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104